收费全文 | 18246篇 |
免费 | 1596篇 |
国内免费 | 43篇 |
医药卫生 | 19885篇 |
2021年 | 215篇 |
2020年 | 201篇 |
2019年 | 239篇 |
2018年 | 349篇 |
2017年 | 269篇 |
2016年 | 273篇 |
2015年 | 333篇 |
2014年 | 430篇 |
2013年 | 646篇 |
2012年 | 713篇 |
2011年 | 720篇 |
2010年 | 483篇 |
2009年 | 544篇 |
2008年 | 750篇 |
2007年 | 742篇 |
2006年 | 780篇 |
2005年 | 681篇 |
2004年 | 675篇 |
2003年 | 656篇 |
2002年 | 686篇 |
2001年 | 642篇 |
2000年 | 655篇 |
1999年 | 592篇 |
1998年 | 327篇 |
1997年 | 347篇 |
1996年 | 349篇 |
1995年 | 250篇 |
1994年 | 186篇 |
1993年 | 229篇 |
1992年 | 388篇 |
1991年 | 353篇 |
1990年 | 375篇 |
1989年 | 353篇 |
1988年 | 364篇 |
1987年 | 332篇 |
1986年 | 347篇 |
1985年 | 303篇 |
1984年 | 222篇 |
1983年 | 185篇 |
1982年 | 120篇 |
1979年 | 172篇 |
1978年 | 166篇 |
1977年 | 144篇 |
1976年 | 125篇 |
1975年 | 161篇 |
1974年 | 184篇 |
1973年 | 132篇 |
1972年 | 139篇 |
1971年 | 141篇 |
1970年 | 122篇 |
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献
Main outcome measures In all subjects expiratory volumes were determined and urinary analysis was conducted for hydroxyproline, calcium, phosphorus, and cortisol levels. Osteocalcin, calcium, phosphorus, cortisol, alkaline phosphatase, and γ-glutamyltransferase levels were measured in blood samples. Bone density of the lumbar spine was determined by means of dual-energy x-ray absorptiometry. Nutrition evaluation was based on a 3-day food diary analyzed using progiciel Nutri 91. The nutritional parameters examined were calcium; phosphorus; magnesium; zinc; vitamins A, C, and D; protein; total fiber; oxalates; energy; caffeine; and alcohol in relation to bone density.
Subjects Thirty-one patients with moderate to severe asthma who had been taking more than 1,000 μg beclomethasone per day or the equivalent for more than 2 years and 27 patients with mild asthma who were taking less than 500 μg beclomethasone per day or the equivalent.
Statistical analyses performed Four factor analysis of variance with hierarchized interactions of four levels, Duncan's test, Pearson correlation coefficients.
Results Blood levels of osteocalcin and protein intake were lower in patients with moderate to severe asthma than in those with mild asthma (P<.05). Significant correlations (P<.02) were observed between bone density and calcium intake (r=.40), phosphorus intake (r=.35), protein intake (r=.30), and serum alkaline phosphatase level (r=−.30). Bone density was not significantly different between the two groups of patients with asthma.
Applications A follow-up of patients with asthma who are taking inhaled corticosteroids is needed to assess bone density, osteocalcin levels, and dietary intakes of calcium. Verify if osteocalcin level decreases over time in patients with moderate to severe asthma, monitor possible modifications in bone density, and verify if the correlation between dietary calcium and bone density is maintained. J Am Diet Assoc. 1997;97:1401–1406. 相似文献